Investigating a protein's role in heart failure development and treatment
Cardiac Myosin Binding Protein-C in Development and Reversal of Heart Failure
This study is looking at a protein called cMyBPC to see how it can help improve heart function in people with heart failure, and it aims to find new ways to treat this condition that affects many Americans.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Texas A&m University Health Science Ctr NIH-funded |
| Lab location | 1 site (College Station, United States) |
| Project ID | NIH-10544998 on NIH RePORTER |
What this research studies
This research focuses on the role of cardiac myosin binding protein-C (cMyBPC) in the development and treatment of heart failure, a condition affecting millions of Americans. The study uses mouse models to explore how the phosphorylation of cMyBPC can improve heart function by enhancing the heart muscle's ability to contract and relax. By examining different phosphorylation sites on the protein, researchers aim to identify new therapeutic targets that could lead to better treatments for heart failure with reduced and preserved ejection fraction. The findings could provide insights into innovative strategies for managing this serious condition.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with heart failure, particularly those with reduced or preserved ejection fraction.
Not a fit: Patients with heart failure caused by non-cardiac factors or those who do not have a diagnosis of heart failure may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that significantly improve heart function and survival rates for patients with heart failure.
How similar studies have performed: Previous research has shown promising results in targeting cardiac myosin binding proteins for heart failure treatment, indicating a potential for success in this approach.
Where this research is happening
College Station, United States
- Texas A&m University Health Science Ctr — College Station, United States (Active)
Researchers
- Principal investigator: Tong, Carl Wei-Chan — Texas A&m University Health Science Ctr
- Study coordinator: Tong, Carl Wei-Chan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.